Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Finished Goods (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Finished Goods for 3 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Finished Goods fell 1.49% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 1.49% decrease, with the full-year FY2025 number at $1.5 million, down 1.49% from a year prior.
  • Finished Goods was $1.5 million for Q4 2025 at Phathom Pharmaceuticals, down from $2.6 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $2.6 million in Q3 2025 to a low of $647000.0 in Q4 2023.
  • A 3-year average of $1.5 million and a median of $1.5 million in 2025 define the central range for Finished Goods.
  • Biggest YoY gain for Finished Goods was 177.27% in 2025; the steepest drop was 1.49% in 2025.
  • Phathom Pharmaceuticals' Finished Goods stood at $647000.0 in 2023, then surged by 128.59% to $1.5 million in 2024, then fell by 1.49% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Finished Goods are $1.5 million (Q4 2025), $2.6 million (Q3 2025), and $2.4 million (Q2 2025).